Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398750 | 1.00 | KIF11 (0.47) | KIF11CTSLCTSBCTSSCTSK | |
| SCHEMBL2396614 | 0.83 | CTSL (0.42) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2396618 | 0.83 | CTSL (0.42) | CTSLCTSBCTSSCTSK | |
| SCHEMBL1272459 | 0.83 | KIF11 (0.56) | KIF11CTSLCTSBCTSSCTSK | |
| SCHEMBL13725978 | 0.83 | KIF11 (0.56) | KIF11CTSLCTSBCTSSCTSK | |
| SCHEMBL1331473 | 0.83 | KIF11 (0.56) | KIF11CTSLCTSBCTSSCTSK | |
| SCHEMBL1272910 | 0.83 | KIF11 (0.56) | KIF11CTSLCTSBCTSSCTSK | |
| SCHEMBL1272460 | 0.83 | KIF11 (0.56) | KIF11CTSLCTSBCTSSCTSK | |
| SCHEMBL2401298 | 0.81 | CTSL (0.37) | CTSLCTSBCTSSCTSK | |
| SCHEMBL1272934 | 0.80 | KIF11 (0.53) | KIF11CTSLDNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013186-B2 | Haloalkyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090023781-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | VIROBAY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023781-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | KIF11 2441/4885CTSL 9/4885CTSB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.